On April 8, 2019, the PEDAC will meet to discuss drug development for testosterone replacement therapy in male adolescents for conditions associated with a deficiency or absence of endogenous testosterone resulting from structural or genetic etiologies (“classic hypogonadism”). The following topics will be considered for discussion: diagnosing male adolescents with classic hypogonadism, evidence to establish efficacy and safety of testosterone replacement therapy in this population, study design, and feasibility considerations for such studies. The committee will not discuss any individual research programs.
Back to All Events
Earlier Event: March 27Cancelled: Pulmonary-Allergy Drugs Advisory Committee
Later Event: April 10Clinical Laboratory Improvement Advisory Committee